Shenzhen Geno-Immune Medical Institute

Country

Ownership: Private

Established: 2015-04-28

Employees: -

Market Cap: -

Website

Clinical Trials

CD19/79b Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: B Cell Malignancies

Interventions: Biological: bi-4SCAR CD19/79b T cells

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 60

Registration Number: NCT05436509

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CD19/70 Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: B Cell Malignancies

Interventions: Biological: bi-4SCAR CD19/70 T cells

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT05436496

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: Cancer Disease

Interventions: Biological: bi-4SCAR PSMA/CD70 T cells

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 60

Registration Number: NCT05437341

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

GD2/CD56 Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: Malignant Disease

Interventions: Biological: bi-4SCAR GD2/CD56 T cells

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 60

Registration Number: NCT05437328

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

GD2/PSMA Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Biological: bi-4SCAR GD2/PSMA T cells

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 60

Registration Number: NCT05437315

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CD19/22 Bi-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: B Cell Malignancies

Interventions: Biological: bi-4SCAR CD19/22 T cells

First Posted Date: 2022-06-27

Last Posted Date: 2022-06-27

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 60

Registration Number: NCT05432882

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

Phase 1

Recruiting

Conditions: T-Cell Acute Lymphoblastic Leukemia

Interventions: Biological: Antigen-specific T cells CAR-T/CTL and DCvac

First Posted Date: 2022-03-14

Last Posted Date: 2022-03-15

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT05277753

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

Phase 1

Recruiting

Conditions: B-Cell Acute Lymphoblastic Leukemia

Interventions: Biological: Antigen-specific T cells CART/CTL and DCvac

First Posted Date: 2022-03-02

Last Posted Date: 2022-03-08

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT05262673

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Phase 1

Conditions: Neuroblastoma

Interventions: Biological: GD2, PSMA and CD276 CAR-T cells

First Posted Date: 2020-11-19

Last Posted Date: 2020-11-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04637503

Locations: 🇨🇳
Guangdong Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangzhou, China

and more 1 locations

Combination Immunotherapy Targeting Sarcomas

Phase 1

Conditions: Sarcoma
Ewing Sarcoma
Osteoid Sarcoma

Interventions: Biological: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 20

Registration Number: NCT04433221

Locations: 🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy